Develops drugs for poultry coccidiosis and canine osteoarthritis.
Sep 2025Revenue $209K/yrExpenses $8.67M/yr
No trend
Figures by year
When will Zivo Bioscience be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Sep 2025, revenue was $209K and expenses $8.67M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $157K | $13.5M | −$13.4M |
| Dec 2023 | $27.6K | $7.29M | −$7.26M |
| Dec 2022 | $0.00 | $8.73M | −$8.73M |
| Dec 2021 | $0.00 | $8.65M | −$8.65M |
| Dec 2020 | $20.0K | $8.58M | −$8.56M |
| Dec 2019 | $0.00 | $8.35M | −$8.35M |
| Dec 2018 | $0.00 | $6.13M | −$6.13M |
| Dec 2017 | $0.00 | $6.33M | −$6.33M |
| Dec 2016 | $0.00 | $3.49M | −$3.49M |
| Dec 2015 | $0.00 | $3.06M | −$3.06M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.